title: FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
abstract: OBJECTIVE
  The aim of our study was to explore the potential of FcGR genetic polymorphisms as a predictor of adalimumab efficacy in rheumatoid arthritis (RA) patients.
  
  
  METHODS
  The study population was composed of 302 Dutch RA patients receiving adalimumab therapy. The FcGR2A (R131>H; rs1801274) and FcGR3A (F158>V; rs396991) genetic variants were genotyped using the TaqMan(®) allelic discrimination technology. Treatment outcome was evaluated with the use of the 28-joint disease activity score criteria (DAS28) and good response and remission were classified according to European League Against Rheumatism (EULAR) criteria.
  
  
  RESULTS
  Comparing allelic frequencies between responders and nonresponders, the presence of the FcGR2A*R allele was associated with EULAR good response at 14 weeks (p = 0.017, odds ratio: 1.53, 95% CI: 1.08-2.17). No significant association was found for FcGR3A, with good response or remission. The combined effect of both FcGR2A and FcGR3A SNPs showed a trend for association with EULAR good response (p-value = 0.041, odds ratio: 1.38, 95% CI: 1.01-1.89).
  
  
  CONCLUSIONS
  Our results indicate that FcGR polymorphisms could be a determinant of adalimumab efficacy in RA patients. Original submitted 28 July 2014; Revision submitted 19 December 2014.
authors.affiliation: Department of Clinical Pharmacy, San Cecilio University Hospital, Instituto de Investigación Biosanitaria ibs. Granada, Granada, Spain.
authors.forename: Cristina Lucía
authors.initials: CL
authors.lastname: Dávila-Fajardo
authors.forename: Tahar
authors.initials: T
authors.lastname: van der Straaten
authors.forename: Rene
authors.initials: R
authors.lastname: Baak-Pablo
authors.forename: Catalina
authors.initials: C
authors.lastname: Medarde Caballero
authors.forename: Jose
authors.initials: J
authors.lastname: Cabeza Barrera
authors.forename: Tom W
authors.initials: TW
authors.lastname: Huizinga
authors.forename: Henk-Jan
authors.initials: HJ
authors.lastname: Guchelaar
authors.forename: Jesse J
authors.initials: JJ
authors.lastname: Swen
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D017452:Receptors, IgG / Q000235:genetics*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: C445323:FCGR2A protein, human; C496124:FCGR3A protein, human; D017452:Receptors, IgG; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
keywords: FcGR; SNP; adalimumab; pharmacogenetics; rheumatoid arthritis; single nucleotide polymorphism